BofA raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $247 from $230 and keeps a Buy rating on the shares. Favorable Phase 3 topline data from the HERIZON-GEA-01 study in gastric cancer suggest Ziihera is an approvable drug in first-line GEA, a market the firm estimates could equate to greater than $600M in the U.S. and greater than $1.1B in global peak sales, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals’ Promising Pipeline and Strong Trial Results Lead to Buy Rating and Raised Price Objective
- Zymeworks Stock (ZYME) Soars on Positive Results for Cancer Drug Ziihera, Top Analysts Boost Price Targets
- Jazz Pharmaceuticals price target raised to $225 from $185 at Jefferies
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Jazz Pharmaceuticals rises 20.6%